CWD Limited to consider FY26 results on May 29, 2026
CWD Limited will hold a board meeting on May 29, 2026, via video conference to approve audited financial results for the year and half-year ended March 31, 2026. The board will also consider the allotment of equity shares from warrant conversions. The trading window is closed and will reopen 48 hours post-meeting.

*this image is generated using AI for illustrative purposes only.
CWD Limited has scheduled a meeting of its Board of Directors on Friday, May 29, 2026, to approve the audited financial results for the half-year and year ended March 31, 2026. The meeting will be held via Video Conference (VC) or Other Audio-Visual Means (OAVM). The Board will also consider the allotment of equity shares following the conversion of warrants, a move that could alter the company's equity capital structure.
The agenda includes the review and approval of standalone and consolidated financial statements for the specified periods. Additionally, the Board will address any other business with the permission of the Chair. The trading window for dealing in the company's securities is currently closed in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015. It will reopen 48 hours after the conclusion of the Board Meeting.
The meeting notice was submitted to BSE Limited under Regulation 29(1) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. Tejas Kothari, Joint Managing Director & CFO, signed the intimation on behalf of the company.
Key Agenda Items
| Agenda Item | Description |
|---|---|
| Financial Results | Audited results (Standalone and Consolidated) for half-year and year ended March 31, 2026 |
| Equity Allotment | Allotment of equity shares pursuant to conversion of warrants |
| Other Business | Any other item with the permission of the Chair |
Historical Stock Returns for CWD
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.42% | +4.43% | -7.70% | -21.02% | +54.27% | +689.31% |
What is the expected dilution impact on existing shareholders resulting from the conversion of warrants?
How will the audited financial results for the year ended March 31, 2026, compare to the company's previous annual performance?
What strategic initiatives or capital allocation plans does the company intend to pursue following the equity infusion?


































